MoneyWorks4Me

Biocon informs about company statement

14 Oct 2026 Evaluate
Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE. 
Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1237.65
Cipla 1313.80
Lupin 1957.00
Zydus Lifesciences 1117.30
View more..